| For: | Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World J Gastroenterol 2024; 30(40): 4393-4398 [PMID: 39494094 DOI: 10.3748/wjg.v30.i40.4393] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i40/4393.htm |
| Number | Citing Articles |
| 1 |
Yibin Cai, Jiaying Li, Shenyu Chen, Hui Zhang, Jie Tan, Hao Li, Shuyuan Zhang, Boran Li, Qin Wei, Chenshi Lin, Xuesong Zhong, Xiuhua You, Chao Qin, Chao Teng, Jie Liu. Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies. International Journal of Pharmaceutics: X 2026; doi: 10.1016/j.ijpx.2026.100596
|
| 2 |
Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra. Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease. Cells 2024; 13(24) doi: 10.3390/cells13242055
|
| 3 |
Issa S Al-Amri, Abdulaziz Y AlKindi, Saeed Mohammadi, Samira Farhadi. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World Journal of Biological Chemistry 2025; 16(1): 104535 doi: 10.4331/wjbc.v16.i1.104535
|
| 4 |
Rong Hu, Dan Liu, Xiaofei Sun, Zhong Yu. New drugs approved by European medicines agency during 2024. European Journal of Medicinal Chemistry 2025; 294 doi: 10.1016/j.ejmech.2025.117761
|
| 5 |
Iuliana Popescu. PPARevolution. First PPARδ Agonist and a Dual PPARα/PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis. Journal of Cellular and Molecular Medicine 2025; 29(21) doi: 10.1111/jcmm.70948
|
| 6 |
Liver Cirrhosis - Current Challenges and Emerging Technologies. 2026; doi: 10.5772/intechopen.1012482
|
| 7 |
Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng. Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model. Journal of Translational Internal Medicine 2026; 14(1) doi: 10.1515/jtim-2026-0007
|
| 8 |
Mengyao Duan, Ying Wu, Jie Zhang, Saman Azeem, Yao Dong, Zhonghui Gai, Jianguo Zhu, Shuguang Fang, Shaobin Gu. Weizmannia coagulans BC179 Alleviates Post-Alcohol Discomfort May via Taurine-Related Metabolism and Antioxidant Regulation: A Randomized, Double-Blind, Placebo-Controlled Trial. Antioxidants 2025; 14(9) doi: 10.3390/antiox14091038
|
| 9 |
Chen-Ying Zhu, Pei-Han Yu, Qi Sun, De-Fei Hong, Chang Yang, Hua Naranmandura. Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights. Pharmacological Research 2025; 218 doi: 10.1016/j.phrs.2025.107862
|